The Efficacy of Intravenous Acetaminophen During Perioperative Neurosurgery Period

NCT ID: NCT01739699

Last Updated: 2021-11-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2017-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective randomized double blinded trial study involving 128 patients undergoing any craniotomy procedure at Evanston Hospital. The patients will be randomized by the sealed envelope technique. The anesthesiologist and nurses who will be administering the placebo or intravenous acetaminophen will be blinded to the group in which patients are assigned.

The following general perioperative data will be recorded: patient information/preoperative data, procedural information, postoperative information, and overall satisfaction of pain management at 24 hours after surgery.

Based on a pilot study (N-20) we expect that 25% of the placebo treated patients will require no opioids in the first 24 hour postoperative period. With the use of intravenous acetaminophen, it is hypothesized that the number of patients that do not require opioids in the first 24 hours after surgery will double.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective randomized double blinded trial study involving 128 patients undergoing any craniotomy procedure at Evanston Hospital. The patients will be randomized by the sealed envelope technique. The anesthesiologist and nurses who will be administering the placebo or intravenous acetaminophen will be blinded to the group in which patients are assigned.

The following information will be recorded for each patient enrolled in this study:

* Patient information/Preoperative Data

* Age, sex, height, weight,
* Disease specific information
* Primary diagnosis
* Pertinent medical history
* Medications
* Pertinent changes in patient status
* Procedural information

* Operation type
* Preoperative anesthetic medications
* Induction meds, intra-operative anesthetic meds, and post-operative anesthetic meds
* Duration of Surgery and Intubation
* Amount of dilaudid equivalent narcotics
* Postoperative Information

* Amount of narcotics administered in the PACU
* Amount of narcotics administered in the first 24 hour postoperative period
* Amount of non-narcotic analgesics administered in the first 24 hour postoperative period
* Time to first rescue analgesic in the PACU
* Amount of first rescue medication recorded
* Assessment of Pain Intensity at T0.5 (30min into PACU stay) and T24 (24 hours after end of surgery) (A 10-cm VAS scale will be used and labeled no pain at its left terminus and worst pain imaginable at its right terminus)
* Temperature in degrees centigrade every 8 hours for 24hours.
* CAM-ICU is performed by ICU nurses to detect delirium in patients every 8 hours and will be documented on a data collection sheet for the first 24 hours
* RASS is a sedation scoring system that is used in our ICU and is documented every 8 hours by ICU nursing. We will record the RASS score for the first 24 hours on a data collection sheet as documented by the ICU nurse.
* Overall satisfaction score at 24 hrs. "Overall satisfaction with pain management" (verbal rating score: scale 1 - 100)

Based on a pilot study (N-20) we expect that 25% of the placebo treated patients will require no opioids in the first 24 hour postoperative period. With the use of intravenous acetaminophen, it is hypothesized that the number of patients that do not require opioids in the first 24 hours after surgery will double.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Craniotomy Brain Surgery

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

craniotomy brain surgery acetaminophen Tylenol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acetaminophen

Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.

Group Type EXPERIMENTAL

Acetaminophen

Intervention Type DRUG

Placebo

Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.

Group Type OTHER

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetaminophen

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tylenol normal saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject are able to provide informed consent prior to participation in the study
* Subjects must be scheduled to undergo elective open craniotomy procedure of \> 2 hour duration
* Subjects must be \>18 years old but less than 90 years old
* Subjects must have an American Society of Anesthesiologists (ASA) class I-IV
* Subjects must have the ability to communicate meaningfully with the investigator staff and read/understand the study procedures and the use of pain scales

Exclusion Criteria

* Subjects used opioids or tramadol daily for \>7 days before study medication administration
* Subjects had been treated with any of the following within 14 days of surgery: chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian
* Subjects who have a chronic pain condition, significant medical disease or laboratory abnormality that in the investigator's judgment could compromise the subject's welfare
* Subjects with known hypersensitivity to opioids, acetaminophen or the inactive ingredients
* Subjects with known or suspected history of alcohol or drug abuse or dependence in the previous 2 years prior to the proposed surgery
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cadence Pharmaceuticals

INDUSTRY

Sponsor Role collaborator

Endeavor Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Steven Greenberg

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Greenberg, MD

Role: PRINCIPAL_INVESTIGATOR

NorthShore University Health Sytem - Evanston Hospital Department of Anesthesia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NorthShore University HealthSystem

Evanston, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EH11-380

Identifier Type: -

Identifier Source: org_study_id